Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Eur J Haematol ; 77(2): 150-6, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16800840

RESUMO

BACKGROUND: The clinical severity in thalassaemia major (TM) depends on the underlying mutations of the beta-globin gene and the degree of iron overload. OBJECTIVE: The aim of the study was to investigate the impact of genotype on the development of endocrine complications in TM in our center. SUBJECTS AND METHODS: 126 (62 males, 64 females) thalassaemic patients of Greek Cypriot origin with a mean age of 31.2 (17-68) yr were included in the study. All patients, who were on the standard treatment protocol, were subsequently divided into two groups according to their genotype, group A (92): TM with no mitigating factor and group B (34): TM carrying one or more mitigating factors in the beta- and/or alpha-globin genes. Iron overload calculation was based on the amount of red cell consumption and the mean ferritin level over a 12-year period. Statistical analysis was performed with the SPSS program. RESULTS: Patients in group A, who were consuming larger amounts of blood on transfusions, were more likely to develop hypogonadism (P = 0.001) compared with patients in group B, despite their similar mean ferritin levels. The incidence of other endocrinopathies (short stature, hypothyroidism, and diabetes mellitus) was similar in the two groups. The prevalence of hypothyroidism in splenectomized patients was significantly higher (P = 0.005), whereas the presence of hypogonadism, impaired glucose homeostasis and insulin resistance, although more frequent, was not statistically significant. The clinical severity of TM had no impact on bone mineral density (BMD) in both men and women. BMD was only influenced by gonadal function. CONCLUSIONS: This study demonstrates that the underlying genetic defect in TM is a contributing factor for gonadal dysfunction, because the patients with the more severe defects have a greater rate of iron loading through higher red cell consumption.


Assuntos
Doenças Ósseas Metabólicas/etiologia , Diabetes Mellitus/etiologia , Nanismo/etiologia , Genótipo , Globinas/genética , Hipogonadismo/etiologia , Hipotireoidismo/etiologia , Talassemia beta/genética , Adolescente , Adulto , Idoso , Glicemia/análise , Transfusão de Sangue/estatística & dados numéricos , Densidade Óssea , Doenças Ósseas Metabólicas/epidemiologia , Terapia por Quelação/efeitos adversos , Terapia Combinada , Chipre/epidemiologia , Análise Mutacional de DNA , Diabetes Mellitus/epidemiologia , Nanismo/epidemiologia , Etnicidade/genética , Feminino , Ferritinas/sangue , Predisposição Genética para Doença , Humanos , Hipogonadismo/epidemiologia , Hipotireoidismo/epidemiologia , Incidência , Resistência à Insulina/genética , Ferro/metabolismo , Quelantes de Ferro/efeitos adversos , Quelantes de Ferro/uso terapêutico , Sobrecarga de Ferro/etiologia , Masculino , Ciclo Menstrual , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Esplenectomia , Reação Transfusional , Talassemia beta/complicações , Talassemia beta/tratamento farmacológico , Talassemia beta/cirurgia , Talassemia beta/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA